Optimum Hires Nick Bastin Further Strengthening Leadership Team
Optimum Strategic Communications (“Optimum”), the specialist life sciences communications consultancy, today announced that it has hired Nick Bastin, the veteran financial and corporate communicator, to join as a permanent member of its team.
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Deal value of up to US$525 million
Novo Holdings co-led…
eTheRNA Announces Relocation and Expansion of R&D Facility
GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”),…
Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models
Findings published in the peer-reviewed journal ACS Chemical…
Novo Holdings’ Principal Investments Provides Update on a Record Year
Deployed close to EUR 1.9 billion of equity*
Expanded portfolio…
Bionical Emas: Ian Fraser appointed as Executive Vice President, Clinical Development.
Bionical Emas, a global Contract Research Organisation (CRO)…
Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic
BioCity, Scotland, 30th March 2022
£1 million grant will…
Novo Holdings and HealthQuad invest in Qure.ai
The funding will accelerate the AI-driven healthcare company’s…
Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
• Started clinical trial with lead candidate RJx-01 for treating…
eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service
NIEL, BELGIUM, March 29, 2022, eTheRNA Manufacturing, a specialist…
EXACT Therapeutics Announces Appointment of Dr Per Walday as Chief Executive Officer
OSLO/LONDON, 28 March 2022: EXACT Therapeutics AS (“EXACT-Tx”,…
DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product
Turku, Finland – 28 March 2022: – DelSiTech Ltd, the leading…
Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences
GDT002 shown to have a potent anti-tumor activity across a…
Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020
Copenhagen, Denmark – Novo Holdings realised Total Income…
Futura Announces Collaboration with Menarini Korea to Commercialise MED3000 in South Korea
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a…
Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute
genex Bone Graft Substitute upgraded with a new closed-mixing…
Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
Precirix NV, a clinical-stage biotechnology company developing…
Leucid Bio Chief Scientific Officer John Maher publishes new research on pCAR technology
New data highlight the strength and versatility of Leucid’s…
Neuraxpharm appoints Tom Coogan as new Country Manager for Ireland
Europe’s leading central nervous system specialty company…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York